

REMARKS

Reconsideration of the present Application in view of the Amendment and Request for Continued Examination enclosed herewith and the following remarks is respectfully requested. An Amendment and Response were submitted to the U.S. Patent and Trademark Office (PTO) on March 7, 2006 in response to an Office Action dated February 1, 2006. As noted in the Advisory Action mailed by the PTO on March 20, 2006, the Remarks were considered and the Amendments were entered. Claims 58, 69, and 71-74 are presently pending. Claim 58 has been amended to define more clearly certain embodiments of the invention. Support for this amendment is provided throughout the specification and, therefore, does not constitute new matter. Support for the amended claim may be found throughout the specification, for example, at page 35, lines 13-18 and page 42, lines 14-22.

**Rejections Under 35 U.S.C. § 112, First Paragraph (Written Description)**

Claims 58, 69, and 71-74 stand rejected under 35 U.S.C. § 112, first paragraph, for allegedly failing to comply with the written description requirement. The Advisory Action asserts that the claims contain new subject matter that was not described in the specification. Specifically, the Action asserts that the specification does not provide adequate written support for “at least seven cell surface marker antigens” on line 7 of claim 58.

Applicants respectfully traverse this rejection and submit that the present claims as amended herein are described in the instant specification in sufficient detail such that a person skilled in the art would appreciate that Applicants had possession of the invention as claimed and that no new matter has been introduced into the application. Applicants’ presently claimed embodiment of the invention is related to an assay device for identifying a leukemia of T-cell, B-cell, or myeloid lineage in a subject. The device comprises (a) a solid support; and (b) an array of immunoglobulin molecules, or derivatives thereof, immobilized to discrete regions on the solid support (*see, e.g.,* specification, page 34, line 30 through page 35, line 7). The array comprises from 7 to about 1000 discrete regions, and each region is comprised of immunoglobulins that are specific for a cell surface marker antigen or for different regions of the cell surface marker antigen (*see, e.g.,* specification, page 35, lines 13-18; page 41, lines 7-15;

page 42, lines 14-22). The specification further clearly describes cell surface marker antigens that are useful for identifying a leukemia of T-cell, B-cell, or myeloid lineage in a subject, and that these cell surface marker antigens may be selected from those listed in Table 4 (*see, e.g.*, specification, at page 54, lines 6-19; page 61, lines 5-29; page 63, lines 21-24; Table 4; and Figure 7).

Accordingly, Applicants submit that the present claims are fully supported by the instant specification and do not constitute new matter, thus meeting the written description requirements under 35 U.S.C. § 112, first paragraph. Applicants therefore respectfully request that this rejection be withdrawn.

Applicants respectfully submit that all claims in the application are allowable. Favorable consideration and a Notice of Allowance are earnestly solicited. In the event that the Examiner believes a teleconference will facilitate prosecution of this case, the Examiner is invited to telephone the undersigned at 206-622-4900.

Respectfully submitted,

SEED Intellectual Property Law Group PLLC

*Maureen Hordt (Reg. No 48,903)*

*for*

---

William T. Christiansen, Ph.D.  
Registration No. 44,614

MJR:teb

701 Fifth Avenue, Suite 6300  
Seattle, Washington 98104-7092  
Phone: (206) 622-4900  
Fax: (206) 682-6031

766434\_1.DOC